AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29797907
Drug: Tongdu Tiaoshen
RxNorm normalized name: MENTHOL 3 g TRANSDERMAL PATCH [TIANHE GUBEN YAOSHEN TIE GAO]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongdu Tiaoshen needles therapy
Trial: 26975954
Drug: Finasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5 mg daily for 2 weeks)
Trial: 11333096
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no agent)
Trial: 23902782
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1500 mg/d during pregnancy)
Trial: 12748567
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CRM and vestibular rehabilitation (VR)
Trial: 487688
Drug: Atenolol, 50
RxNorm normalized name: Atenolol, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol, 50 mg daily
Trial: 14982562
Drug: Propofol 60
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 60 mg ml(-1)
Trial: 7536155
Drug: Octreotide 0.1
RxNorm normalized name: octreotide 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 0.1 mg subcutaneously 120 and 30 min before EST and four hours after
Trial: 25404215
Drug: Text message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text message intervention (SMS sent at h48, D7, D15 and monthly)
Trial: 2654467
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (control group)
Trial: 20886733
Drug: Transcranial bitemporal
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial bitemporal magnetotherapy (TcMT) combined with reduced basic therapy (driptan 2.5 mg twice a day)
Trial: 20886733
Drug: Placebo TcMT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo TcMT with basic therapy
Trial: 16648332
Drug: Sertraline (N=14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (N=14 overweight and obese subjects)
Trial: 12953327
Drug: Transdermal delivery
RxNorm normalized name: nitroglycerin 5 mg in 1 d TRANSDERMAL PATCH [Nitroglycerin Transdermal Delivery System]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal delivery of reproductive steroids
Trial: 22453589
Drug: Zinc citrate
RxNorm normalized name: Zinc Citrate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc citrate 50 mg and phytase 3,000 PU
Trial: 22453589
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate 10 mg
Trial: 12385443
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg SP-303
Trial: 20582906
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg Ginkgo extract (EGb 761)
Trial: 18026906
Drug: Weekly gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly gemcitabine (125 mg/m(2)) with cisplatin (40 mg/m(2)) and pelvic radiotherapy
Trial: 10609984
Drug: d-amphetamine (indirect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (indirect dopamine agonist)
Trial: 2002251
Drug: Digital intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital intradermal injections of histamine
Trial: 2002251
Drug: Digital intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital intradermal injections of substance P
Trial: 2002251
Drug: Digital intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital intradermal injections of calcitonin gene‐related peptide
Trial: 2002251
Drug: Digital intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital intradermal injections of compound 48/80
Trial: 1694913
Drug: Metoprolol (100-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100-300 mg/day)
Trial: 1694913
Drug: Pindolol (5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (5-15 mg/day)
Trial: 26684670
Drug: Comparison treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison treatment
Trial: 25885650
Drug: Escitalopram (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10-20 mg daily for 24 weeks)
Trial: 15131767
Drug: Fat group
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat group - standard meal plus a fat supplement of 300 kcal from different types of fat (butter, sunflower margarine, olive oil)
Trial: 15131767
Drug: CHO group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO group - standard meal plus a supplement of 300 kcal from different types of CHO (bread, coke, fruit)
Trial: 18367653
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of ANG II (5.0 ng.kg(‐1).min(‐1)) in PA
Trial: 18367653
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of ANG II (5.0 ng.kg(‐1).min(‐1)) in NC
Trial: 18367653
Drug: Simultaneous infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous infusion of nitroprusside and ANG II in PA
Trial: 18367653
Drug: Simultaneous infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous infusion of nitroprusside and ANG II in NC
Trial: 15776134
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) started at 1 mg/kg/day, titrated to 2.5 mg/kg/day after TPMT assay not performed (group 1)
Trial: 12457784
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg per day)
Trial: 2412262
Drug: Leucocyte interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucocyte interferon in daily doses of 3 x 10(6) I.U.i.m
Trial: 2412262
Drug: Irradiation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation of both lungs in a calculated mean central dose of 10 Gy in 4 weeks in combination with bleomycin and vincristine
Trial: 22845045
Drug: Two-compound ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-compound ointment (calcipotriol 50 μg/g; betamethasone dipropionate 0.5 mg/g)
Trial: 22845045
Drug: Calcipotriol cream
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol cream (50 μg/g)
Trial: 15652441
Drug: OAD morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAD morphine (mean 238 +/- 319 mg q24h)
Trial: 15652441
Drug: twice-daily CR
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: twice-daily CR morphine (mean 119 +/- 159 mg q12h)
Trial: 15652441
Drug: OAD morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAD morphine
Trial: 10452766
Drug: Sublingual standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual standardized Parietaria judaica extract (n = 20)
Trial: 8552268
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg/die monotherapy
Trial: 29170074
Drug: IV antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV antibiotics for 10 days
Trial: 29170074
Drug: IV antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV antibiotics for 14 days
Trial: 23096129
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment of AIS (hybrid and pedicle screws alone)
Trial: 23096129
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment of AIS
Trial: 8896139
Drug: Zidovudine treatment
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine treatment after cross-over from placebo
Trial: 6350313
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HDMTX) with citrovorum factor rescue (CFR) and cis-platinum
Trial: 6350313
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of adriamycin or bleomycin, cyclophosphamide, and dactinomycin (BCD)
Trial: 6350313
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate with citrovorum factor rescue
Trial: 30630722
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention (communication, systematic pain management, medication review, activities) with standardized education and on-site training for 4 months.
Trial: 17725246
Drug: Atenolol, 50
RxNorm normalized name: Atenolol, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol, 50 mg/day
Trial: 24467247
Drug: Steam vapor
RxNorm normalized name: Warm Steam Vaporizer 1.2 Gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steam vapor treatment
Trial: 11880962
Drug: 3-day treatment
RxNorm normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-day treatment with valacyclovir (500 mg twice daily)
Trial: 11880962
Drug: 5-day treatment
RxNorm normalized name: 30 day Acne Treatment Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day treatment with valacyclovir (500 mg twice daily)
Trial: 9663357
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg once daily (n = 213)
Trial: 9663357
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg once daily (n = 219)
Trial: 3145820
Drug: L-dopa (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (500 mg orally)
Trial: 24212915
Drug: Infliximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5 mg/kg) infusion seven days before antiviral therapy
Trial: 23019296
Drug: Vaginal micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal micronized progesterone tablets
Trial: 17545700
Drug: HAART plus
RxNorm normalized name: Tri-Heart Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART plus systemic chemotherapy
Trial: 12200525
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP; 500 micro g twice daily, n=14)
Trial: 7986629
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene (OH) twice a week until plaque was present at less than 20% of sites
Trial: 7013054
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid (600 mg daily)
Trial: 6342784
Drug: Indomethacin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (75 mg daily)
Trial: 28545757
Drug: Family-Focused Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-Focused Treatment for Childhood Depression (FFT-CD)
Trial: 11433085
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) at 0.8 ± 0.1 mg/kg body weight per day for 3.3 ± 0.6 years
Trial: 11433085
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (before HCTZ therapy)
Trial: 9773140
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ibuprofen (i.v.)
Trial: 7880604
Drug: Doxorubicin 20
RxNorm normalized name: DOXOrubicin 20 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 20 mg weekly
Trial: 7880604
Drug: Doxorubicin 20
RxNorm normalized name: DOXOrubicin 20 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 20 mg weekly + high-dose medroxyprogesterone acetate (1000 mg daily)
Trial: 2906479
Drug: Olsalazine, 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olsalazine, 1.5 g/day
Trial: 2906479
Drug: Sulphasalazine, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine, 3 g/day
Trial: 31225673
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (combined nutraceutical containing bergamot extract, phytosterols, vitamin C, and chlorogenic acid)
Trial: 31225673
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (low-dose or high-dose)
Trial: 23629979
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) injection (8 ml injected into the suprapatellar joint)
Trial: 26774901
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PRP injection)
Trial: 21556038
Drug: High-dose ursodeoxycholic
RxNorm normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ursodeoxycholic acid (UDCA) 28-30 mg/kg/day
Trial: 14610443
Drug: Participation in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participation in Project Read (treatment group)
Trial: 9602591
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg kg‐1
Trial: 31202211
Drug: Food Supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food Supplement (FS)
Trial: 31202211
Drug: No Supplementary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Supplementary Treatment (NoST)
Trial: 26545141
Drug: Methylprednisolone 2mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 2mg/kg loading dose followed by 1mg/kg/day continuous infusion from days 1 to 7
Trial: 24793711
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 1.5% mepivacaine solution (n=31)
Trial: 18538112
Drug: Vildagliptin/metformin fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin/metformin fixed-dose combination tablets (50/500 mg)
Trial: 18538112
Drug: Vildagliptin/metformin fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin/metformin fixed-dose combination tablets (50/850 mg)
Trial: 18538112
Drug: Vildagliptin/metformin fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin/metformin fixed-dose combination tablets (50/1,000 mg)
Trial: 18538112
Drug: Vildagliptin/metformin fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin/metformin fixed-dose combination tablets
Trial: 15191512
Drug: Percutaneous acetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous acetic acid injection (PAI)
Trial: 10604045
Drug: Diclofenac free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac free acid suspension (50 mg)
Trial: 6764119
Drug: Levamisole hydrochloride
RxNorm normalized name: Levamisole Hydrochloride
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole hydrochloride (150 mg daily for 3 consecutive days every fortnight)
Trial: 28678148
Drug: No levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No levosimendan (L-group)
Trial: 26498398
Drug: Long-lasting cerebral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-lasting cerebral vasospasm (LL-CVS) treatment
Trial: 19550337
Drug: Dexmedetomidine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1.0 microg kg(‐1)) infusion
Trial: 19550337
Drug: Fentanyl (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1.0 microg kg(‐1)) infusion
Trial: 12372195
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (nebulized epinephrine and humidified oxygen)
Trial: 3894245
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy (Prednisolone 1 mg/kg/day for 9 days over 3 cycles)
Trial: 3894245
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy (Prednisolone)
Trial: 26335706
Drug: Palonosetron (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron (0.075 mg i.v.; n = 35)
Trial: 21372623
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) - 6 weekly 90-min sessions
Trial: 15983390
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg daily
Trial: 18323548
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of exemestane 25 mg daily with celecoxib 400 mg twice daily
Trial: 18323548
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of exemestane and celecoxib
Trial: 3592139
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 7.5 mg daily for 3 weeks
Trial: 3592139
Drug: Injection with
RxNorm normalized name: Temsirolimus 25mg/1mL Solution for injection with Diluent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection with 2 ml suspension of betamethasone dipropionate and betamethasone disodium phosphate (Diprospan)
Trial: 1729575
Drug: No iron
RxNorm normalized name: No Iron Multivitamin with Minerals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No iron supplement (Control group)
Trial: 6727693
Drug: High oestrogen
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oestrogen dose (oestriol and 17 beta‐oestradiol)
Trial: 6727693
Drug: Medium oestrogen
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium oestrogen dose (oestriol and 17 beta‐oestradiol)
Trial: 6727693
Drug: Low oestrogen
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low oestrogen dose (oestriol and 17 beta‐oestradiol)
Trial: 19007923
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) for perfectionism
Trial: 10214534
Drug: Avitriptan 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avitriptan 150 mg
Trial: 2088202
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (CC) 5 ml
Trial: 31344520
Drug: Virtual Learning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Learning Collaborative (VLC) - 18-month intensive group-based with monthly learning sessions
Trial: 28464343
Drug: Gaviscon Double
RxNorm normalized name: Gaviscon
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaviscon Double Action (20 mL after meals and bedtime)
Trial: 28464343
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 mL after meals and bedtime)
Trial: 25410648
Drug: 2‐L polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐L polyethylene glycol with ascorbic acid (2‐L PEG/Asc)
Trial: 21316048
Drug: Anastrozole 5
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole 5 mg
Trial: 21316048
Drug: Anastrozole 20
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole 20 mg
Trial: 21316048
Drug: Anastrozole 30
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole 30 mg
Trial: 12915798
Drug: Sucrose solution
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose solution (2 mL)
Trial: 12915798
Drug: Water (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (2 mL)
Trial: 16935035
Drug: Inhaled furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled furosemide (40 mg)
Trial: 21063131
Drug: Pramipexole 0.5
RxNorm normalized name: pramipexole 0.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.5 mg/day
Trial: 21976367
Drug: Denosumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (60 mg) every 6 months for 3 years